The goal of this clinical research study is to find the highest tolerable dose of vemurafenib
that can be given in combination with carboplatin and paclitaxel patients with advanced
cancer. The safety of the study drug combination will also be studied.
Vemurafenib is designed to block a protein (called mutated BRAF) that is only found in moles
(spots) of the skin and certain types of cancer cells. This drug may slow the growth of or
kill these cells.
Carboplatin is designed to slow the growth of cancer cells by stopping them from making new
DNA (the genetic material of cells).
Paclitaxel is designed to slow the growth of cancer cells by stopping them from dividing into
new cells.